---
id: 189
title: Mpox (Monkeypox) Virus
category: emerging_infections
subcategory: viral
tags: [mpox, monkeypox, orthopoxvirus, TPOXX, JYNNEOS, tecovirimat]
difficulty: medium
---

## Question

How is mpox diagnosed and managed? Use **"Vesiculopustular Rash + Lymphadenopathy, PCR → Tecovirimat (Severe), JYNNEOS Vaccine"** framework.

## Answer

### **Mpox Virus Overview:**

**Organism:** Orthopoxvirus (related to smallpox, vaccinia, cowpox)

**Transmission:**
- **Close contact:** Skin-to-skin, respiratory secretions, contaminated fomites
- **Sexual contact:** Common in 2022 outbreak (MSM networks)
- **Animal-to-human:** Rodents, primates (endemic Africa)

### **Clinical Presentation:**

**Prodrome (1-4 Days Before Rash):**
- **Fever, chills, headache, myalgia, fatigue**
- **Lymphadenopathy** (inguinal, cervical, axillary) - distinguishes from smallpox

**Rash (Hallmark):**
- **Vesiculopustular lesions** (firm, deep-seated, well-circumscribed, umbilicated)
- **Progression:** Macules → papules → vesicles → pustules → scabs (over 2-4 weeks)
- **Distribution:** Centrifugal (face/extremities, including palms/soles) OR **anogenital** (2022 outbreak)
- **All lesions in same stage** (vs. varicella, which has lesions in different stages)

**Atypical Presentations (2022 Outbreak):**
- **Localized genital/perianal lesions** (may not disseminate)
- **Proctitis** (anorectal pain, tenesmus, bloody discharge)
- **Minimal or no prodrome**

**Severe Disease (Rare):**
- **Immunocompromised** (HIV CD4 <200)
- **Confluent lesions, sepsis, encephalitis, pneumonitis**

### **Diagnosis:**

**PCR (Gold Standard):**
- **Lesion swab** (vesicle fluid, pustule, crust) - preferred
- **Oropharyngeal swab** (if oral lesions)
- **Rectal swab** (if proctitis)

**Serologies:** NOT useful for acute diagnosis

**Histopathology:** Intracytoplasmic inclusion bodies (Guarnieri bodies)

### **Treatment:**

**Supportive Care (Most Cases):**
- **Pain control, wound care**
- **Isolation** (until all lesions crusted + resolved)

**Tecovirimat (TPOXX) - Antiviral:**
- **Indications:**
  - **Severe disease** (extensive lesions, immunocompromised, mucosal involvement)
  - **High-risk** for severe disease (HIV CD4 <200, eczema, pregnancy, children <8 years)
  - **Anatomic complications** (ocular, oral with dysphagia, genital with urinary retention)

**Dosing:**
- **Adults ≥120 kg:** 600mg PO BID × 14 days
- **Adults 40-120 kg:** 600mg PO BID × 14 days
- **Weight-based** for children

**Access:** Available via **FDA Expanded Access IND** (contact CDC/local health department)

**Other Antivirals (Not First-Line):**
- **Cidofovir, brincidofovir:** Limited data, significant toxicity

### **Vaccination:**

**JYNNEOS (MVA-BN, Imvanex/Imvamune):**
- **Live, non-replicating modified vaccinia Ankara vaccine**
- **2 doses (0, 28 days)** subcutaneous

**Indications:**

**Pre-Exposure Prophylaxis (PrEP):**
- **High-risk:** Laboratory workers handling orthopoxviruses, healthcare workers in endemic areas

**Post-Exposure Prophylaxis (PEP):**
- **Within 4 days** of exposure (ideally) - can prevent disease
- **4-14 days** post-exposure - may reduce severity
- **Close contacts** of confirmed cases (sexual, household, healthcare workers with unprotected exposure)

**Expanded PrEP (2022 Outbreak):**
- **MSM with multiple partners** or recent bacterial STI
- **Sex workers**
- **Persons at risk** in outbreak settings

**ACAM2000 (Older Smallpox Vaccine):**
- **Live, replicating vaccinia**
- **Contraindicated:** Immunocompromised, eczema, pregnancy
- **Reserved** for PrEP if JYNNEOS unavailable

### **Infection Control:**

**Isolation:**
- **Contact + droplet precautions**
- **Until all lesions crusted and resolved** + new skin layer underneath

**PPE:**
- **Gown, gloves, surgical mask, eye protection**

**Sexual Activity:**
- **Abstain until lesions resolved** (transmission risk persists while lesions present)

## Key Points

### **Lymphadenopathy = Key Clue:**
- **Distinguishes from smallpox** (which does NOT cause lymphadenopathy)
- **Inguinal, cervical, axillary**

### **Lesions in Same Stage:**
- **All lesions progress together** (macules → papules → vesicles → pustules → scabs)
- **vs. Varicella:** Lesions in different stages simultaneously

### **Anogenital Lesions (2022 Outbreak):**
- **Localized genital/perianal** (may not disseminate)
- **Proctitis** common (anorectal pain, bloody discharge)
- **Transmission via sexual contact**

### **Tecovirimat (TPOXX):**
- **For severe disease or high-risk**
- **FDA Expanded Access IND** (contact CDC)
- **600mg PO BID × 14 days**

### **JYNNEOS Vaccine:**
- **PEP within 4 days** of exposure (prevents disease)
- **2 doses (0, 28 days)** for PrEP

### **Clinical Pearls:**
- **Vesiculopustular rash + lymphadenopathy** (inguinal, cervical)
- **Lesions in same stage** (vs. varicella)
- **PCR of lesion swab** (gold standard diagnosis)
- **Tecovirimat (TPOXX)** for severe/high-risk (FDA Expanded Access)
- **JYNNEOS vaccine:** PEP (within 4 days), PrEP (MSM, sex workers, high-risk)
- **Isolation until lesions crusted + resolved**

## Sources

- [CDC: Mpox Guidelines 2024]
- [IDSA: Mpox Management 2024]

## Media

N/A
